PTC Therapeutics (PTCT) Insider Gregory Sells $693K of Stock

On June 26, 2026, Almstead Neil Gregory, the Chief Technical Ops Officer at PTC Therapeutics, Inc. (NasdaqGS: PTCT), sold 8,130 shares of the company. The shares were sold at an average price of $85.26, totaling approximately $693,151. This transaction was part of a planned sale.

Insider Buying and Selling at PTC Therapeutics, Inc.

Neil Gregory's recent sale was not his only transaction. On the same day, he also executed a planned sale of 8,130 shares at the same price. Previously, on June 25, 2026, he sold 20,960 shares at an average price of $85.97, while also buying 20,960 shares at an average price of $38.11.

PTC Therapeutics, Inc. Stock Up 33.7%

Shares of PTC Therapeutics traded near $81.57 on Wednesday. The company has a market capitalization of approximately $7 billion and a forward P/E ratio of 30.3, reflecting its valuation relative to future earnings. The stock has seen a 52-week range between $43.18 and $87.50. PTC's 50-day moving average stands at $72.22, and its 200-day moving average is $70.94. The company's current ratio is 2.44, indicating its ability to cover short-term liabilities.

Analysts Set New Price Targets

On June 9, 2026, Citigroup assumed coverage on PTC Therapeutics with a 'buy' rating and set a price target of $108. Previously, Jefferies upgraded the stock to 'buy' on May 27, 2026, with a target of $85. TD Cowen also upgraded the stock to 'buy' on May 8, 2026, setting a target of $90. The consensus among analysts is a 'buy', with a mean target price of $93.93 from 14 opinions.

Other Institutional Activity in PTC Therapeutics

BlackRock, Inc. grew its holdings in PTC Therapeutics by 169,652 shares, ending with 12,948,717 shares valued at about $882.2 million. Janus Henderson Group PLC significantly boosted its stake by 48.3%, adding 2,342,101 shares to reach a total of 7,193,433 shares worth approximately $490 million. Vanguard Portfolio Management LLC opened a new position with 4,804,594 shares valued at $327.3 million. Meanwhile, State Street Corp increased its holdings by 140,393 shares, resulting in a total of 4,346,519 shares valued at $296.1 million.

About PTC Therapeutics

PTC Therapeutics, Inc., based in Warren, New Jersey, is a biopharmaceutical company specializing in the discovery and development of medicines for rare disorders. The company markets several treatments, including Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza for AADC deficiency. PTC Therapeutics is also involved in developing therapies for conditions like Huntington's disease and Friedreich's ataxia. The company collaborates with major pharmaceutical firms and distributes its products globally.

Bottom Line

Almstead Neil Gregory's recent insider sale at PTC Therapeutics highlights ongoing executive activity within the company. As investors track these movements, it's important to remember that the disclosed transactions may be part of planned sales. PTC Therapeutics continues to be a focus in the biotech sector, with analysts maintaining a positive outlook on its stock, underpinned by the company's strategic partnerships and innovative pipeline.